|View printer-friendly version|
|October 22, 2000 3:32 p.m.|
|Teva Received Final Approval for Doxazosin Mesylate|
TO BE SHIPPED IMMEDIATELY
Jerusalem, Israel, October 22, 2000 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has received from the U.S. FDA final approval to manufacture and market Doxazosin Mesylate 1, 2, 4 and 8 mg Tablets.